← Eichor
Condition: Refractory Malignant Solid Neoplasm Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Refractory Malignant Solid Neoplasm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 · 3 location(s) · RasCal Therapeutics, Inc. · NCT04678648Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07510815Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT05053971CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase 1/Phase 2 · 2 location(s) · St. Jude Children's Research Hospital · NCT05468359Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unrese
Phase 1 · 4 location(s) · National Cancer Institute (NCI) · NCT05111561Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Phase 1 · 1 location(s) · Kyushu University · NCT05608148Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Soli
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT06620302A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBE
Phase 1/Phase 2 · 63 location(s) · Merck Sharp & Dohme LLC · NCT06941272TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancrea
Phase 1 · 1 location(s) · University of California, Davis · NCT07189195MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Phase 1 · 1 location(s) · Mayo Clinic · NCT06911008AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Phase 1 · 2 location(s) · University of Southern California · NCT05791448RAPA-201 Therapy of Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Rapa Therapeutics LLC · NCT05144698Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 · 1 location(s) · Florida International University · NCT05857969Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Phase N/A · 3 location(s) · National Cancer Institute (NCI) · NCT03739827IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
NA · 4 location(s) · Fred Hutchinson Cancer Center · NCT04515810GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
Phase 1/Phase 2 · 1 location(s) · China-Japan Friendship Hospital · NCT06173219Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
Phase 1 · 2 location(s) · West China Hospital · NCT07040943A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activ
Phase 1 · 1 location(s) · Xingchen Peng · NCT07100210A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Phase 2 · 16 location(s) · Memorial Sloan Kettering Cancer Center · NCT05985161YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases
Phase 2 · 1 location(s) · Tianjin First Central Hospital · NCT07697937AOH1996 for the Treatment of Refractory Solid Tumors
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT05227326Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT05631886Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Sol
Phase 1/Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT06320405
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.